Nivasorexant

Nivasorexant (ACT-539313) is an orally active, blood-brain barrier penetrant, selective orexin OX1R inhibitor. Nivasorexant specifically blocks central OX1Rs without affecting OX2Rs, and exhibits competitive inhibitory activity against CYP2C8, CYP2C9, CYP2C19 and CYP3A4 (IC50 values are 25 μM, 8.6 μM, 1.6 μM, 19 μM/44 μM, respectively). Nivasorexant significantly reduces binge-like eating behavior of highly palatable food in rat models and has long-acting properties. Nivasorexant shows no relevant off-target activity against over 130 selected proteins, exhibits favorable safety profiles, and can be used for studies related to binge eating disorder .


Cat. No.: EX-A10364	Purity: >98%

	Chemical structure of Nivasorexant

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order
1g	get quote	Inquire

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	ACT-539313
CAS No.	1435480-40-2
Purity	>98%
Formula	C23H23N7O2
Mol Weight	429.4744
Color	White to off-white
State	Solid
Solubility	Soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder -20℃ 3 years, 4℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Steiner MA, et al. Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge-eating disorder. Int J Eat Disord. 2024;57(7):1418-1432. [2]. Berger B, et al. Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects. Pharmacol Res Perspect. 2023;11(5):e01143.
CoA	CoA of Nivasorexant

Smiles:	O=C(C1=CC=C(C)C=C1N2N=CC=N2)N3[C@H](CC4=CC=CC(N5N=CC=N5)=C4)COCC3


		Search